BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15448667)

  • 1. Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
    Kern W; Voskova D; Schnittger S; Schoch C; Hiddemann W; Haferlach T
    Hematol J; 2004; 5(5):410-8. PubMed ID: 15448667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
    Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
    Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia.
    Voskova D; Schnittger S; Schoch C; Haferlach T; Kern W
    Leuk Lymphoma; 2007 Jan; 48(1):80-8. PubMed ID: 17325851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aberrant immunophenotypes in 126 patients with acute leukemia].
    He JJ; Li YH; Sun XJ; Wan SG; Xu J; Su L; Tian D
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1032-6. PubMed ID: 17956685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A; Gillis D; Hissaria P; Lewis I
    Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia.
    Lacombe F; Durrieu F; Briais A; Dumain P; Belloc F; Bascans E; Reiffers J; Boisseau MR; Bernard P
    Leukemia; 1997 Nov; 11(11):1878-86. PubMed ID: 9369421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
    Drach J; Drach D; Glassl H; Gattringer C; Huber H
    Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
    Zelezníková T; Babusíková O
    Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis].
    Liu YR; Chen SS; Chang Y; Fu JY; Zhang LP; Wang H; Li LD; Zhu HH; Liu GL; Lu DP; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):853-7. PubMed ID: 17096875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
    Kern W; Voskova D; Schoch C; Hiddemann W; Schnittger S; Haferlach T
    Blood; 2004 Nov; 104(10):3078-85. PubMed ID: 15284114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunophenotypes in 115 patients with acute myeloid leukemia by multi-color flow cytometry].
    Wang XB; Yao JX; Zheng JE; Liu J; Li XQ; He YL; Yu JM; Yang J; Wei J; Liu ZP; Huang SA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):250-3. PubMed ID: 15854286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes.
    Olaru D; Campos L; Flandrin P; Nadal N; Duval A; Chautard S; Guyotat D
    Cytometry B Clin Cytom; 2008 Jan; 74(1):17-24. PubMed ID: 18061947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.